Healthcare Industry News: SuturaGel
News Release - July 18, 2017
Fagron, Inc. Announces Launch Of LETS GEL KIT(TM) for Rapid Topical AnesthesiaNew Unit-Dose Gel Alternative to TAC Available for Suture Preparations
ST. PAUL, Minn., July 18, 2017 -- (Healthcare Sales & Marketing Network) -- Fagron, Inc. introduces LETS GEL KIT™, a line extension to their industry-leading topical anesthesia convenience pack used for the prevention of pain when suturing. The newly available LETS GEL KIT™ includes SuturaGel™, a specially formulated gel designed to minimize medication run-off from the treatment area. Also included in the easy-to-use convenience pack are pre-weighed active ingredients--lidocaine, epinephrine, tetracaine, sodium metabisulfate--and topical syringes to prepare 33 – 3 mL individual doses.
With a focus on pharmacists and prescribers, Fagron, Inc. offers unique solutions that add significant value in the treatment of patients. Fagron's LETS GEL KIT™ provides a convenient, time-saving solution that minimizes waste and improves the delivery of medication to the treatment site. "We are extremely pleased to provide hospitals and urgent care centers with a pharmacist-friendly enhancement to our already successful LETS KIT," stated Rita Hoke, President of Fagron North America. "This innovation marks an important step forward in Fagron's strategic growth."
Fagron, Inc. routinely introduces innovative products to the market based on research completed in their own R&D center located in St. Paul. The R&D team works closely with healthcare providers to deliver optimized compounding solutions with high quality results. Fagron continuously advances knowledge through scientific studies, which are frequently published in renowned scientific journals. To find out more, visit www.fagron.us.
About Fagron, Inc.
Fagron, Inc., is headquartered in St. Paul, Minnesota. Since 1980, Fagron, Inc. has been an FDA-registered pharmaceutical supplier, adhering strictly to current Good Manufacturing Practices (cGMP). Bulk Pharmaceutical Ingredients (BPI) are purchased from reputable, registered, and validated manufacturers. Fagron's strategy is focused on the optimisation and innovation of pharmaceutical compounding. As a R&D scientific pharmaceutical compounding supplier, Fagron wants to widen the therapeutic scope of the prescriber to enable tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist and improves the patient's quality of life. Contact Fagron, Inc. today at us.fagron.com/en-us/contact.
About Fagron North America
Fagron acts locally and thinks globally. As the world's leading pharmaceutical compounding company, Fagron operates in 32 countries. Fagron North America is an innovative group of scientific pharmaceutical companies that focus on optimizing and innovating pharmaceutical compounding. They are fully integrated with facilities that specialize in 503A Compounding, 503B Human Drug Outsourcing, and provide pharmacists with high quality APIs, supplies, education and technical support. Fagron North America is headquartered in St. Paul, Minnesota. Experience more with Fagron. For more information, visit www.fagron.us/
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.